Answers are grounded in this paper and cite their sources.
Background: In 2018, WHO recommended single-dose typhoid conjugate vaccines (TCVs) for typhoid-endemic countries. Emerging evidence of waning immunity has raised questions about optimal vaccination age and booster doses. A follow-up multi-model study evaluated vaccination schedules, focusing on booster strategies. Here, we expand findings from one of four modelling groups, estimating the global and regional health impact of TCV schedules.,Methodology: We developed an agent-based typhoid transmission model using the open-source Starsim toolbox. The model captures subclinical and acute infections, chronic carriers, and natural and vaccine-derived immunity, with age- and sex-specific parameters and outcomes. The model was calibrated to three incidence archetypes (medium, high, and very high) and two vaccine-derived immunity durations (fast and slow waning). Countries were mapped to archetypes based on national typhoid burden. We compared no vaccination with four strategies: routine vaccination at 9 months, 9 months with a booster at 5 years, 2 years, and 5 years, each with a catch-up campaign. Cases, deaths, and DALYs averted were estimated globally and across GBD super-regions over 10 years.,Results: Globally, up to 29.6 million cases and 8.3 million DALYs could be averted with routine vaccination at 9 months plus a 5-year booster. Earlier vaccination and longer-lasting immunity generally increased impact. Under fast waning, vaccination at 2 years averted more cases and DALYs than vaccination at 9 months or 5 years, particularly in high-incidence settings where burden was greatest among children aged 2–<5 years. Boosters provided additional benefits, especially with fast waning. South Asia accounted for the largest share of global impact, followed by Sub-Saharan Africa.,Conclusion: TCV impact varies substantially by incidence and immunity duration. Booster strategies offer additional benefits, particularly in high-burden settings and with rapid waning, highlighting the need to tailor schedules to local epidemiology and improve evidence on TCV immunity duration.
No takes yet. Share an insight, caveat, or question.
Muellenmeister et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: